Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097113 | 0.79 | RAB9A (0.41) | CCR1 | |
| SCHEMBL5097109 | 0.79 | RAB9A (0.41) | CCR1 | |
| SCHEMBL5094817 | 0.78 | MEN1 (0.37) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3658864 | 0.76 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CCR1 | |
| SCHEMBL7535279 | 0.76 | MAOA (0.52) | CHRM2CHRM1CHRM3 | |
| SCHEMBL11730842 | 0.75 | SIGMAR1 (0.44) | SIGMAR1HRH3PRCPDRD2DRD4 | |
| SCHEMBL8816954 | 0.71 | MAOA (0.47) | PRCPCHRM2CHRM1CHRM3CCR1 | |
| SCHEMBL11730192 | 0.70 | SIGMAR1 (0.40) | SIGMAR1HRH3PRCPDRD2HTR1A | |
| SCHEMBL5096972 | 0.68 | MAOA (0.44) | SIGMAR1HTR1A | |
| SCHEMBL2010012 | 0.68 | HTR2A (0.66) | SIGMAR1HRH3DRD2DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | SIGMAR1 7/4885HRH3 736/4885PRCP 1366/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | SIGMAR1 7/4885HRH3 736/4885PRCP 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.